What is Retatrutide?
Retatrutide, identified in scientific literature as LY3437943, is an investigational peptide developed by Eli Lilly. It's engineered as a triple-receptor agonist, meaning it's studied for its interaction with three separate receptor systems in a single molecule: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. This distinguishes it from single-target compounds like semaglutide (GLP-1 only) or dual-target compounds like tirzepatide (GLP-1/GIP). Retatrutide carries a C20 fatty diacid moiety that enables albumin binding, extending its half-life in research models.
As of 2026, Retatrutide remains in Phase 3 clinical development and is not approved by the FDA, EMA, or MHRA for any use. It has no legal status as an approved medication anywhere.
What it's studied for in research
Retatrutide's triple-receptor profile has made it a focus of ongoing metabolic and endocrine pathway research. Published and ongoing studies examine its interaction with:
- GLP-1 receptor signaling — associated with appetite regulation, gastric emptying, and glucose-dependent insulin secretion pathways.
- GIP receptor signaling — studied for its role in insulin release and beta-cell function in metabolic research models.
- Glucagon receptor signaling — investigated for effects on energy expenditure, hepatic glycogen metabolism, and lipolysis.
Because it engages all three pathways simultaneously, researchers use Retatrutide to study combined metabolic effects that aren't observable with single- or dual-agonist compounds — a research angle specific to this molecule's structure.
How we test it
Every batch of Retatrutide we list — both the 10mg and 30mg format — is sent to an independent third-party laboratory for HPLC purity and content analysis before it's made available for purchase. Full certificates of analysis are published in our COA library, searchable by lot number.
Related reading
Retatrutide vs Tirzepatide vs Semaglutide: how they differ →
Frequently asked
What sizes are available?
We currently carry Retatrutide in 10mg and 30mg lyophilized vials.
What form does it ship in?
As a lyophilized (freeze-dried) powder, requiring reconstitution with a sterile diluent — such as bacteriostatic water — before use in laboratory protocols.
Is Retatrutide FDA-approved?
No. It remains an investigational compound in Phase 3 clinical trials as of 2026 and has no regulatory approval anywhere. It is sold here strictly as a laboratory research reference material, not as a medication.
Is a COA available for every batch?
Yes. Every lot we sell is independently tested before listing, and the full report is published in our COA library before that batch goes on sale.